Patient satisfaction with fluticasone propionate/salmeterol (FSC) HFA with an integrated dose counter

W. R. Lincourt, C. Crim, K. K. Sheth, N. W. Locantore, J. R. Carranza Rosenzweig (Research Triangle Park, Lafayette, United States Of America)

Source: Annual Congress 2005 - Inhaler devices: challenges and solutions
Session: Inhaler devices: challenges and solutions
Session type: Thematic Poster Session
Number: 862
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. R. Lincourt, C. Crim, K. K. Sheth, N. W. Locantore, J. R. Carranza Rosenzweig (Research Triangle Park, Lafayette, United States Of America). Patient satisfaction with fluticasone propionate/salmeterol (FSC) HFA with an integrated dose counter. Eur Respir J 2005; 26: Suppl. 49, 862

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of fluticasone propionate/salmeterol DISKUS and fluticasone propionate DISKUS and HFA in children
Source: Eur Respir J 2005; 26: Suppl. 49, 161s
Year: 2005

Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

Real world handling performance of fluticasone propionate/salmeterol HFA MDI with an integrated dose counter in subjects with asthma or COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 127s
Year: 2005

Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013

Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma
Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Year: 2020


Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON)
Source: Eur Respir J 2003; 22: Suppl. 45, 259s
Year: 2003

Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

Efficacy of salmeterol/fluticasone propionate (50/100mcg/day) delivered via the Diskus™ and MDI in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Financial benefits of fluticasone propionate/salmeterol 250/50 mcg fixed dose combination over tiotropium in elderly managed COPD patient
Source: Annual Congress 2010 - Management of airway disease
Year: 2010

²Stepping down[/quot] from fluticasone propionate/salmeterol 100/50mcg Diskus® results in loss of asthma control
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Performance of salmeterol/fluticasone propionate HFA MDIs with and without counter are comparable
Source: Eur Respir J 2005; 26: Suppl. 49, 126s
Year: 2005

Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006

Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 357s
Year: 2007

Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management
Source: Eur Respir J 2002; 20: Suppl. 38, 388s
Year: 2002